

# Chapter 9

## HISTOLOGIC TYPES OF SELECTED SITES OF CANCER

The number and relative proportion of the specific histological types of cancer (for Microscopically Diagnosed Cases) as appropriate for the selected anatomical sites of cancer are given below.

### Tongue (ICD-10: C01-C02)

**Table 9.1: Number (#) and Relative Proportion (%) of Different Histologic Types**

Histologic Type	TMH		KMIO		CI (WIA)		RCC - TVM		AMC		BBCI		PGIMER		BRAIRCH	
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
<b>MALES</b>																
Neoplasm Malignant	2	0.5	19	21.8	-	-	14	2.7	5	6.3	8	1.7	-	-	-	-
Carcinomas	1	0.2	2	2.3	-	-	3	0.6	-	-	3	0.6	8	1.5	5	4.0
Verrucous Carcinomas	-	-	-	-	-	-	-	-	-	-	-	-	2	0.4	1	0.8
Squamous Cell Carc.	427	98.8	65	74.7	99	99.0	508	96.2	75	93.8	453	97.4	509	97.7	119	94.4
Adeno Carcinoma	1	0.2	-	-	1	1.0	1	0.2	-	-	-	-	1	0.2	1	0.8
Others	1	0.2	1	1.1	-	-	2	0.4	-	-	1	0.2	1	0.2	-	-
<b>All Microscopic</b>	<b>432</b>	<b>100.0</b>	<b>87</b>	<b>100.0</b>	<b>100</b>	<b>100.0</b>	<b>528</b>	<b>100.0</b>	<b>80</b>	<b>100.0</b>	<b>465</b>	<b>100.0</b>	<b>521</b>	<b>100.0</b>	<b>126</b>	<b>100.0</b>
<b>FEMALES</b>																
Neoplasm Malignant	3	3.0	-	-	-	-	5	2.5	-	-	4	3.5	-	-	-	-
Carcinomas	-	-	1	6.3	-	-	2	1.0	-	-	-	-	3	5.6	1	3.4
Verrucous Carcinomas	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Squamous Cell Carc.	97	96.0	15	93.8	40	100.0	196	96.1	29	100.0	111	96.5	49	90.7	28	96.6
Adeno Carcinoma	-	-	-	-	-	-	-	-	-	-	-	-	1	1.9	-	-
Others	1	1.0	-	-	-	-	1	0.5	-	-	-	-	1	1.9	-	-
<b>All Microscopic</b>	<b>101</b>	<b>100.0</b>	<b>16</b>	<b>100.0</b>	<b>40</b>	<b>100.0</b>	<b>204</b>	<b>100.0</b>	<b>29</b>	<b>100.0</b>	<b>115</b>	<b>100.0</b>	<b>54</b>	<b>100.0</b>	<b>29</b>	<b>100.0</b>

**Mouth (ICD-10: C03-C06)****Table 9.2: Number (#) and Relative Proportion (%) of Different Histologic Types**

Histologic Type	TMH		KMIO		CI (WIA)		RCC - TVM		AMC		BBCI		PGIMER		BRAIRCH			
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%		
<b>MALES</b>																		
Neoplasm Malignant	5	0.7	2	2.3	1	0.8	12	1.8	4	3.5	1	0.2	-	-	-	-	-	-
Carcinomas	3	0.4	2	2.3	-	-	14	2.1	-	-	2	0.5	8	2.8	2	1.4		
Verrucous Carcinomas	6	0.8	3	3.4	1	0.8	10	1.5	3	2.6	19	4.4	2	0.7	4	2.7		
Squamous Cell Carc.	707	97.1	78	88.6	123	96.1	606	92.4	106	93.0	408	94.0	277	95.8	139	94.6		
Adeno Carcinoma	2	0.3	1	1.1	1	0.8	5	0.8	-	-	1	0.2	1	0.3	-	-		
Others	5	0.7	2	2.3	2	1.6	9	1.4	1	0.9	3	0.7	1	0.3	2	1.4		
<b>All Microscopic</b>	<b>728</b>	<b>100.0</b>	<b>88</b>	<b>100.0</b>	<b>128</b>	<b>100.0</b>	<b>656</b>	<b>100.0</b>	<b>114</b>	<b>100.0</b>	<b>434</b>	<b>100.0</b>	<b>289</b>	<b>100.0</b>	<b>147</b>	<b>100.0</b>		
<b>FEMALES</b>																		
Neoplasm Malignant	-	-	1	0.7	2	3.3	2	0.6	2	3.6	-	-	-	-	-	-	-	-
Carcinomas	3	1.5	6	4.0	1	1.6	3	0.9	-	-	-	-	2	2.9	1	3.0		
Verrucous Carcinomas	2	1.0	3	2.0	1	1.6	9	2.7	-	-	8	3.7	-	-	1	3.0		
Squamous Cell Carc.	178	91.8	140	92.7	56	91.8	311	92.3	53	96.4	201	93.5	60	87.0	30	90.9		
Adeno Carcinoma	2	1.0	1	0.7	-	-	5	1.5	-	-	4	1.9	3	4.3	1	3.0		
Others	9	4.6	-	-	1	1.6	7	2.1	-	-	2	0.9	4	5.8	-	-		
<b>All Microscopic</b>	<b>194</b>	<b>100.0</b>	<b>151</b>	<b>100.0</b>	<b>61</b>	<b>100.0</b>	<b>337</b>	<b>100.0</b>	<b>55</b>	<b>100.0</b>	<b>215</b>	<b>100.0</b>	<b>69</b>	<b>100.0</b>	<b>33</b>	<b>100.0</b>		

**Pharynx (ICD-10: C09-C10 and C12-C14)****Table 9.3: Number (#) and Relative Proportion (%) of Different Histologic Types**

Histologic Type	TMH		KMIO		CI (WIA)		RCC - TVM		AMC		BBCI		PGIMER		BRAIRCH			
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%		
<b>MALES</b>																		
Neoplasm Malignant	8	3.1	59	39.3	2	2.5	52	14.6	27	8.7	15	1.0	1	0.2	-	-		
Carcinomas	2	0.8	4	2.7	3	3.7	11	3.1	2	0.6	7	0.5	21	4.6	10	9.1		
Verrucous Carcinomas	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Squamous Cell Carc.	243	94.9	87	58.0	75	92.6	293	82.1	280	90.3	1454	98.3	419	91.7	96	87.3		
Adeno Carcinoma	1	0.4	-	-	-	-	-	-	1	0.3	-	-	-	-	-	-		
Others	2	0.8	-	-	1	1.2	1	0.3	-	-	3	0.2	16	3.5	4	1.4		
<b>All Microscopic</b>	<b>256</b>	<b>100.0</b>	<b>150</b>	<b>100.0</b>	<b>81</b>	<b>100.0</b>	<b>357</b>	<b>100.0</b>	<b>310</b>	<b>100.0</b>	<b>1479</b>	<b>100.0</b>	<b>457</b>	<b>100.0</b>	<b>110</b>	<b>100.0</b>		
<b>FEMALES</b>																		
Neoplasm Malignant	1	1.9	6	24.0	-	-	7	12.5	7	9.1	3	1.5	1	1.5	-	-		
Carcinomas	-	-	-	-	-	-	1	1.8	-	-	1	0.5	4	5.9	1	6.3		
Verrucous Carcinomas	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Squamous Cell Carc.	51	96.2	18	72.0	37	100.0	48	85.7	69	89.6	201	98.0	63	92.6	15	93.8		
Adeno Carcinoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Others	1	1.9	1	4.0	-	-	-	-	1	1.3	-	-	-	-	-	-		
<b>All Microscopic</b>	<b>53</b>	<b>100.0</b>	<b>25</b>	<b>100.0</b>	<b>37</b>	<b>100.0</b>	<b>56</b>	<b>100.0</b>	<b>77</b>	<b>100.0</b>	<b>205</b>	<b>100.0</b>	<b>68</b>	<b>100.0</b>	<b>16</b>	<b>100.0</b>		

**Oesophagus (ICD-10: C15)****Table 9.4: Number (#) and Relative Proportion (%) of Different Histologic Types**

Histologic Type	TMH		KMIO		CI (WIA)		RCC - TVM		AMC		BBCI		PGIMER		BRAIRCH	
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
<b>MALES</b>																
Neoplasm Malignant	2	0.9	2	2.5	-	-	16	5.4	2	1.1	2	0.2	-	-	-	-
Carcinomas	6	2.8	3	3.7	2	5.7	21	7.0	2	1.1	8	0.9	18	3.7	4	9.1
Squamous Cell Carc.	167	76.6	68	84.0	27	77.1	211	70.8	178	94.7	836	95.4	418	85.5	34	77.3
Adeno Carcinoma	39	17.9	7	8.6	6	17.1	45	15.1	6	3.2	25	2.9	51	10.4	6	13.6
Others	4	1.8	1	1.2	-	-	5	1.7	-	-	5	0.6	2	0.4	-	-
<b>All Microscopic</b>	<b>218</b>	<b>100.0</b>	<b>81</b>	<b>100.0</b>	<b>35</b>	<b>100.0</b>	<b>298</b>	<b>100.0</b>	<b>188</b>	<b>100.0</b>	<b>876</b>	<b>100.0</b>	<b>489</b>	<b>100.0</b>	<b>44</b>	<b>100.0</b>
<b>FEMALES</b>																
Neoplasm Malignant	-	-	-	-	-	-	2	1.7	1	0.8	2	0.5	-	-	-	-
Carcinomas	-	-	-	-	1	2.8	5	4.2	3	2.4	4	1.0	14	3.8	2	5.7
Squamous Cell Carc.	115	92.7	73	100.0	33	91.7	102	85.7	118	94.4	400	97.1	344	93.7	30	85.7
Adeno Carcinoma	8	6.5	-	-	2	5.6	10	8.4	3	2.4	5	1.2	9	2.5	3	8.6
Others	1	0.8	-	-	-	-	-	-	-	-	1	0.2	-	-	-	-
<b>All Microscopic</b>	<b>124</b>	<b>100.0</b>	<b>73</b>	<b>100.0</b>	<b>36</b>	<b>100.0</b>	<b>119</b>	<b>100.0</b>	<b>125</b>	<b>100.0</b>	<b>412</b>	<b>100.0</b>	<b>367</b>	<b>100.0</b>	<b>35</b>	<b>100.0</b>

**Stomach (ICD-10: C16)****Table 9.5: Number (#) and Relative Proportion (%) of Different Histologic Types**

Histologic Type	TMH		KMIO		CI (WIA)		RCC - TVM		AMC		BBCI		PGIMER		BRAIRCH	
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
<b>MALES</b>																
Neoplasm Malignant	5	2.6	2	3.1	-	-	3	0.9	1	1.0	1	0.8	-	-	-	-
Carcinomas	3	1.6	4	6.2	2	3.6	32	9.2	5	5.2	5	4.0	7	6.0	3	6.1
Adeno Carcinomas	132	68.4	47	72.3	46	83.6	282	80.8	82	84.5	99	79.2	74	63.8	36	73.5
Papillary Adeno Carc.	-	-	1	1.5	-	-	2	0.6	2	2.1	5	4.0	2	1.7	-	-
Mucinous Adeno Carc.	-	-	1	1.5	-	-	15	4.3	5	5.2	2	1.6	4	3.4	3	6.1
Signet Ring Cell Carc.	44	22.8	9	13.8	4	7.3	10	2.9	2	2.1	13	10.4	22	19.0	5	10.2
Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Others	9	4.7	1	1.5	3	5.5	5	1.4	-	-	-	-	7	6.0	2	4.1
<b>All Microscopic</b>	<b>193</b>	<b>100.0</b>	<b>65</b>	<b>100.0</b>	<b>55</b>	<b>100.0</b>	<b>349</b>	<b>100.0</b>	<b>97</b>	<b>100.0</b>	<b>125</b>	<b>100.0</b>	<b>116</b>	<b>100.0</b>	<b>49</b>	<b>100.0</b>
<b>FEMALES</b>																
Neoplasm Malignant	6	7.0	1	2.2	-	-	7	5.2	1	1.7	1	1.8	-	-	-	-
Carcinomas	3	3.5	4	8.9	1	4.3	9	6.7	4	6.7	-	-	3	5.5	-	-
Adeno Carcinomas	42	48.8	25	55.6	13	56.5	99	73.9	50	83.3	46	82.1	29	52.7	12	92.3
Papillary Adeno Carc.	-	-	-	-	-	-	-	-	1	1.7	2	3.6	-	-	-	-
Mucinous Adeno Carc.	-	-	-	-	-	-	3	2.2	1	1.7	-	-	4	7.3	-	-
Signet Ring Cell Carc.	35	40.7	13	28.9	4	17.4	14	10.4	3	5.0	7	12.5	9	16.4	1	7.7
Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Others	-	-	2	4.4	5	21.7	2	1.5	-	-	-	-	10	18.2	-	-
<b>All Microscopic</b>	<b>86</b>	<b>100.0</b>	<b>45</b>	<b>100.0</b>	<b>23</b>	<b>100.0</b>	<b>134</b>	<b>100.0</b>	<b>60</b>	<b>100.0</b>	<b>56</b>	<b>100.0</b>	<b>55</b>	<b>100.0</b>	<b>13</b>	<b>100.0</b>

**Lung (ICD-10: C33-C34)****Table 9.6: Number (#) and Relative Proportion (%) of Different Histologic Types**

Histologic Type	TMH		KMIO		CI (WIA)		RCC - TVM		AMC		BBCI		PGIMER		BRAIRCH	
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
<b>MALES</b>																
Neoplasm Malignant	95	20.5	13	15.7	10	23.3	448	39.6	8	21.6	32	10.5	4	0.5	-	-
Large Cell Carcinoma	-	-	-	-	1	2.3	2	0.2	1	2.7	7	2.3	-	-	1	0.7
Undiff/Anaplastic Carc.	1	0.2	-	-	-	-	-	-	-	-	4	1.3	-	-	-	-
Small Cell Carc.	36	7.8	2	2.4	3	7.0	71	6.3	3	8.1	13	4.2	157	21.2	19	12.4
Squamous Cell Carc.	88	19.0	18	21.7	5	11.6	158	14.0	10	27.0	78	25.5	56	7.6	37	24.2
Other Carcinomas	10	2.2	8	9.6	-	-	49	4.3	2	5.4	4	1.3	37	5.0	21	13.7
Adeno Carcinoma	225	48.5	26	31.3	23	53.5	341	30.2	12	32.4	124	40.5	58	7.8	39	25.5
Others	9	1.9	16	19.3	1	2.3	61	5.4	1	2.7	44	14.4	427	57.8	36	23.5
<b>All Microscopic</b>	<b>464</b>	<b>100.0</b>	<b>83</b>	<b>100.0</b>	<b>43</b>	<b>100.0</b>	<b>1130</b>	<b>100.0</b>	<b>37</b>	<b>100.0</b>	<b>306</b>	<b>100.0</b>	<b>739</b>	<b>100.0</b>	<b>153</b>	<b>100.0</b>
<b>FEMALES</b>																
Neoplasm Malignant	51	31.3	4	19.0	-	-	74	26.8	4	26.7	13	13.3	4	2.3	-	-
Large Cell Carcinoma	1	0.6	-	-	1	9.1	-	-	-	-	-	-	-	-	-	-
Undiff/Anaplastic Carc.	-	-	-	-	-	-	-	-	-	-	2	2.0	-	-	-	-
Small Cell Carc.	3	1.8	1	4.8	2	18.2	7	2.5	2	13.3	3	3.1	28	16.4	3	6.5
Squamous Cell Carc.	7	4.3	1	4.8	-	-	12	4.3	3	20.0	9	9.2	3	1.8	4	8.7
Other Carcinomas	7	4.3	1	4.8	1	9.1	13	4.7	-	-	-	-	10	5.8	11	23.9
Adeno Carcinoma	90	55.2	11	52.4	7	63.6	151	54.7	6	40.0	59	60.2	23	13.5	23	50.0
Others	4	2.5	3	14.3	-	-	19	6.9	-	-	12	12.2	103	60.2	5	10.9
<b>All Microscopic</b>	<b>163</b>	<b>100.0</b>	<b>21</b>	<b>100.0</b>	<b>11</b>	<b>100.0</b>	<b>276</b>	<b>100.0</b>	<b>15</b>	<b>100.0</b>	<b>98</b>	<b>100.0</b>	<b>171</b>	<b>100.0</b>	<b>46</b>	<b>100.0</b>

**Bone (ICD-10: C40-C41)****Table 9.7: Number (#) and Relative Proportion (%) of Different Histologic Types**

Histologic Type	TMH		KMIO		CI (WIA)		RCC - TVM		AMC		BBCI		PGIMER		BRAIRCH	
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
<b>MALES</b>																
Neoplasm Malignant	2	1.6	-	-	-	-	1	1.4	2	20.0	-	-	1	1.1	-	-
Sarcomas	-	-	-	-	-	-	1	1.4	6	60.0	2	9.1	13	14.8	8	9.5
Osteosarcomas	92	72.4	8	47.1	10	37.0	36	50.7	1	10.0	9	40.9	16	18.2	46	54.8
Chondrosarcomas	3	2.4	-	-	1	3.7	-	-	1	10.0	-	-	2	2.3	1	1.2
Giant Cell Tumour	1	0.8	2	11.8	5	18.5	-	-	-	-	1	4.5	6	6.8	-	-
Ewing's Sarcoma	8	6.3	4	23.5	6	22.2	26	36.6	-	-	6	27.3	24	27.3	17	20.2
Chondroma	13	10.2	-	-	2	7.4	6	8.5	-	-	1	4.5	7	8.0	1	1.2
Others	8	6.3	3	17.6	3	11.1	1	1.4	-	-	3	13.6	19	21.6	11	13.1
<b>All Microscopic</b>	<b>127</b>	<b>100.0</b>	<b>17</b>	<b>100.0</b>	<b>27</b>	<b>100.0</b>	<b>71</b>	<b>100.0</b>	<b>10</b>	<b>100.0</b>	<b>22</b>	<b>100.0</b>	<b>88</b>	<b>100.0</b>	<b>84</b>	<b>100.0</b>
<b>FEMALES</b>																
Neoplasm Malignant	1	1.4	-	-	-	-	2	2.8	2	40.0	-	-	1	1.9	-	-
Sarcomas	-	-	6	46.2	-	-	-	-	1	20.0	1	9.1	10	19.2	7	17.5
Osteosarcomas	45	64.3	2	15.4	12	48.0	34	47.2	1	20.0	5	45.5	11	21.2	20	50.0
Chondrosarcomas	-	-	-	-	-	-	-	-	-	-	-	-	1	1.9	-	-
Giant Cell Tumour	2	2.9	2	15.4	2	8.0	-	-	-	-	-	-	4	7.7	-	-
Ewing's Sarcoma	1	1.4	1	7.7	10	40.0	31	43.1	-	-	3	27.3	15	28.8	11	27.5
Chondroma	10	14.3	-	-	1	4.0	4	5.6	-	-	2	18.2	1	1.9	1	2.5
Others	11	15.7	2	15.4	-	-	1	1.4	1	20.0	-	-	9	17.3	1	2.5
<b>All Microscopic</b>	<b>70</b>	<b>100.0</b>	<b>13</b>	<b>100.0</b>	<b>25</b>	<b>100.0</b>	<b>72</b>	<b>100.0</b>	<b>5</b>	<b>100.0</b>	<b>11</b>	<b>100.0</b>	<b>52</b>	<b>100.0</b>	<b>40</b>	<b>100.0</b>

## Soft Tissue (ICD 10: C47 &amp; C49)

Table 9.8: Number (#) and Relative Proportion (%) of Different Histologic Types

Histologic Type	TMH		KMIO		CI (WIA)		RCC - TVM		AMC		BBCI		PGIMER		BRAIRCH	
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
<b>MALES</b>																
Neoplasm Malignant	3	2.1	-	-	-	-	2	2.7	1	7.7	2	8.0	4	4.4	2	4.2
Sarcoma NOS	14	10.0	2	16.7	1	4.8	7	9.6	3	23.1	8	32.0	17	18.9	12	25.0
Spindle Cell Sarcoma	14	10.0	1	8.3	4	19.0	21	28.8	2	15.4	7	28.0	1	1.1	-	-
Pleomorphic Cell Carc.	8	5.7	2	16.7	3	14.3	7	9.6	-	-	1	4.0	6	6.7	2	4.2
Fibrous Histiocytoma	-	-	-	-	-	-	-	-	1	7.7	2	8.0	-	-	-	-
Fibrosarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liposarcoma	7	5.0	1	8.3	3	14.3	11	15.1	-	-	2	8.0	4	4.4	3	6.3
Leiomyosarcoma	6	4.3	-	-	1	4.8	-	-	-	-	-	-	6	6.7	3	6.3
Rhabdomyosarcoma	17	12.1	1	8.3	3	14.3	11	15.1	2	15.4	-	-	7	7.8	8	16.7
Synovial Sarcoma	17	12.1	3	25.0	3	14.3	1	1.4	1	7.7	-	-	4	4.4	15	31.3
Neurofibrosarcoma	-	-	-	-	1	4.8	1	1.4	-	-	1	4.0	19	21.1	-	-
Neurilemmona	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Others	54	38.6	2	16.7	2	9.5	12	16.4	3	23.1	2	8.0	22	24.4	3	6.3
<b>All Microscopic</b>	<b>140</b>	<b>100.0</b>	<b>12</b>	<b>100.0</b>	<b>21</b>	<b>100.0</b>	<b>73</b>	<b>100.0</b>	<b>13</b>	<b>100.0</b>	<b>25</b>	<b>100.0</b>	<b>90</b>	<b>100.0</b>	<b>48</b>	<b>100.0</b>
<b>FEMALES</b>																
Neoplasm Malignant	4	4.8	-	-	1	6.3	1	1.8	-	-	1	4.3	3	4.5	-	-
Sarcoma NOS	10	11.9	1	14.3	-	-	4	7.1	1	10.0	5	21.7	15	22.4	8	27.6
Spindle Cell Sarcoma	10	11.9	-	-	1	6.3	12	21.4	-	-	8	34.8	2	3.0	1	3.4
Pleomorphic Cell Carc.	2	2.4	1	14.3	2	12.5	2	3.6	-	-	-	-	2	3.0	1	3.4
Fibrous Histiocytoma	1	1.2	-	-	1	6.3	-	-	2	20.0	1	4.3	2	3.0	1	3.4
Fibrosarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liposarcoma	3	3.6	-	-	2	12.5	5	8.9	2	20.0	-	-	1	1.5	2	6.9
Leiomyosarcoma	1	1.2	-	-	1	6.3	1	1.8	1	10.0	-	-	3	4.5	5	17.2
Rhabdomyosarcoma	6	7.1	1	14.3	3	18.8	9	16.1	1	10.0	1	4.3	11	16.4	4	13.8
Synovial Sarcoma	16	19.0	1	14.3	4	25.0	3	5.4	-	-	-	-	5	7.5	4	13.8
Neurofibrosarcoma	2	2.4	1	14.3	-	-	-	-	-	-	-	-	9	13.4	-	-
Neurilemmona	-	-	-	-	-	-	-	-	-	-	-	-	1	1.5	-	-
Others	29	34.5	2	28.6	1	6.3	19	33.9	3	30.0	7	30.4	13	19.4	3	10.3
<b>All Microscopic</b>	<b>84</b>	<b>100.0</b>	<b>7</b>	<b>100.0</b>	<b>16</b>	<b>100.0</b>	<b>56</b>	<b>100.0</b>	<b>10</b>	<b>100.0</b>	<b>23</b>	<b>100.0</b>	<b>67</b>	<b>100.0</b>	<b>29</b>	<b>100.0</b>

## Female Breast (ICD-10: C50)

**Table 9.9: Number (#) and Relative Proportion (%) of Different Histologic Types**

Histologic Type	TMH		KMIO		CI (WIA)		RCC - TVM		AMC		BBCI		PGIMER		BRAIRCH	
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
Neoplasm Malignant	26	1.7	-	-	14	2.2	22	1.0	1	0.3	1	0.2	1	0.1	-	-
Carcinoma	1	0.1	4	1.3	9	1.4	142	6.6	-	-	2	0.5	19	2.4	25	6.8
Papillary Carcinoma	15	1.0	1	0.3	-	-	4	0.2	2	0.7	-	-	5	0.6	-	-
Squamous Cell Carc.	-	-	1	0.3	-	-	-	-	-	-	3	0.7	7	0.9	1	0.3
Adeno Carcinoma, NOS	3	0.2	1	0.3	2	0.3	6	0.3	3	1.0	-	-	4	0.5	-	-
Mucinous Adeno Carc.	3	0.2	3	1.0	8	1.3	19	0.9	7	2.3	3	0.7	6	0.8	1	0.3
Infiltrating Duct Carc.	1457	94.1	276	92.9	571	91.4	1899	88.8	256	84.2	396	94.3	733	92.1	329	89.4
Medullary Carcinoma	-	-	1	0.3	-	-	-	-	12	3.9	3	0.7	-	-	1	0.3
Lobular Carcinoma	30	1.9	3	1.0	9	1.4	16	0.7	18	5.9	4	1.0	8	1.0	5	1.4
Paget's Disease	4	0.3	1	0.3	1	0.2	2	0.1	1	0.3	-	-	-	-	-	-
Cystosarc Phyllodes	5	0.3	5	1.7	6	1.0	9	0.4	1	0.3	2	0.5	7	0.9	5	1.4
Others	4	0.3	1	0.3	5	0.8	19	0.9	3	1.0	6	1.4	6	0.8	1	0.3
<b>All Microscopic</b>	<b>1548</b>	<b>100.0</b>	<b>297</b>	<b>100.0</b>	<b>625</b>	<b>100.0</b>	<b>2138</b>	<b>100.0</b>	<b>304</b>	<b>100.0</b>	<b>420</b>	<b>100.0</b>	<b>796</b>	<b>100.0</b>	<b>368</b>	<b>100.0</b>

## Cervix (ICD-10: C53)

**Table 9.10: Number (#) and Relative Proportion (%) of Different Histologic Types**

Histologic Type	TMH		KMIO		CI (WIA)		RCC - TVM		AMC		BBCI		PGIMER		BRAIRCH	
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
Neoplasm Malignant	2	0.4	1	0.2	-	-	8	1.2	-	-	3	0.5	-	-	-	-
Carcinomas	2	0.4	25	4.6	5	1.2	20	3.0	2	1.3	5	0.8	11	1.3	13	7.0
Non Kerat Large Cell	40	7.4	48	8.7	176	42.3	208	31.7	61	39.9	371	57.2	200	24.3	76	41.1
Non Kerat Small Cell	-	-	1	0.2	-	-	1	0.2	2	1.3	-	-	-	-	-	-
Kerat Squa. Cell Carc. NOS	13	2.4	36	6.6	86	20.7	218	33.2	18	11.8	19	2.9	210	25.5	30	16.2
Squa. Cell Carc. NOS	424	78.5	389	70.9	82	19.7	126	19.2	42	27.5	207	31.9	335	40.7	48	25.9
Other Squa. Cell Carc.	4	0.7	1	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Adeno Carcinoma	2	0.4	4	0.7	6	1.4	20	3.0	7	4.6	7	1.1	17	2.1	1	0.5
Adeno Squa. Carc.	4	0.7	9	1.6	13	3.1	8	1.2	1	0.7	8	1.2	9	1.1	2	1.1
Others	49	9.1	35	6.4	48	11.5	47	7.2	20	13.1	29	4.5	42	5.1	15	8.1
<b>All Microscopic</b>	<b>540</b>	<b>100.0</b>	<b>549</b>	<b>100.0</b>	<b>416</b>	<b>100.0</b>	<b>656</b>	<b>100.0</b>	<b>153</b>	<b>100.0</b>	<b>649</b>	<b>100.0</b>	<b>824</b>	<b>100.0</b>	<b>185</b>	<b>100.0</b>

**“If necessity is the mother of invention, scientifically developed production is the mother of scientific research”**

*- Arthur Edwin Kennelly*

**Ovary (ICD-10: C56)****Table 9.11: Number (#) and Relative Proportion (%) of Different Histologic Types**

Histologic Type	TMH		KMIO		CI (WIA)		RCC - TVM		AMC		BBCI		PGIMER		BRAIRCH	
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
Neoplasm Malignant	33	13.7	3	2.2	1	1.0	22	7.0	6	7.3	6	4.0	6	1.6	-	-
Carcinomas	4	1.7	14	10.4	10	9.5	33	10.5	4	4.9	2	1.3	15	4.1	11	14.3
Other Carcinomas	-	-	1	0.7	4	3.8	2	0.6	-	-	-	-	-	-	-	-
Papillary Carcinoma	-	-	3	2.2	-	-	1	0.3	1	1.2	-	-	1	0.3	1	1.3
Squamous Cell Carc.	2	0.8	2	1.5	-	-	-	-	2	2.4	-	-	7	1.9	-	-
Adeno Carcinoma	40	16.6	21	15.7	44	41.9	131	41.7	13	15.9	81	54.0	91	24.7	19	24.7
Papillary Adeno Carc.	3	1.2	9	6.7	5	4.8	30	9.6	6	7.3	8	5.3	11	3.0	2	2.6
Clear Cell Adeno Carc.	5	2.1	2	1.5	6	5.7	7	2.2	-	-	2	1.3	7	1.9	-	-
Endometrioid Carc.	14	5.8	3	2.2	2	1.9	9	2.9	-	-	2	1.3	6	1.6	-	-
Papi/Serous Cyst	115	47.7	58	43.3	15	14.3	42	13.4	29	35.4	23	15.3	147	39.8	29	37.7
Muc Adeno/Cystadeno	7	2.9	6	4.5	8	7.6	15	4.8	16	19.5	9	6.0	19	5.1	2	2.6
Granulosa Cell Tumour	-	-	4	3.0	5	4.8	1	0.3	1	1.2	2	1.3	8	2.2	2	2.6
Sarcomas	-	-	1	0.7	-	-	2	0.6	-	-	-	-	2	0.5	-	-
Stromal Tumours	-	-	-	-	-	-	-	-	-	-	-	-	1	0.3	-	-
Dysgerminoma	3	1.2	-	-	1	1.0	7	2.2	-	-	2	1.3	6	1.6	5	6.5
Endodermal Sinus Tum.	3	1.2	3	2.2	2	1.9	-	-	2	2.4	5	3.3	3	0.8	-	-
Teratomas	6	2.5	-	-	1	1.0	3	1.0	-	-	5	3.3	12	3.3	1	1.3
Others	6	2.5	4	3.0	1	1.0	9	2.9	2	2.4	3	2.0	27	7.3	5	6.5
<b>All Microscopic</b>	<b>241</b>	<b>100.0</b>	<b>134</b>	<b>100.0</b>	<b>105</b>	<b>100.0</b>	<b>314</b>	<b>100.0</b>	<b>82</b>	<b>100.0</b>	<b>150</b>	<b>100.0</b>	<b>369</b>	<b>100.0</b>	<b>77</b>	<b>100.0</b>

**Kidney (ICD-10: C64)****Table 9.12: Number (#) and Relative Proportion (%) of Different Histologic Types**

Histologic Type	TMH		KMIO		CI (WIA)		RCC - TVM		AMC		BBCI		PGIMER		BRAIRCH	
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
<b>MALES</b>																
Neoplasm Malignant	5	6.0	2	10.0	-	-	9	11.4	-	-	-	-	-	-	-	-
Carcinoma NOS	1	1.2	-	-	-	-	3	3.8	-	-	-	-	-	-	-	-
Transitional Cell Carc.	-	-	1	5.0	-	-	3	3.8	-	-	1	20.0	1	1.4	-	-
Adeno Carcinoma	8	9.5	2	10.0	-	-	-	-	-	-	-	-	2	2.7	-	-
Clear Cell Adeno Carc.	55	65.5	7	35.0	8	72.7	53	67.1	2	66.7	3	60.0	28	37.8	6	37.5
Renal Cell Carcinoma	-	-	1	5.0	-	-	-	-	-	-	-	-	1	1.4	-	-
Nephroblastoma	10	11.9	4	20.0	2	18.2	5	6.3	1	33.3	-	-	33	44.6	9	56.3
Others	5	6.0	3	15.0	1	9.1	6	7.6	-	-	1	20.0	9	12.2	1	6.3
<b>All Microscopic</b>	<b>84</b>	<b>100.0</b>	<b>20</b>	<b>100.0</b>	<b>11</b>	<b>100.0</b>	<b>79</b>	<b>100.0</b>	<b>3</b>	<b>100.0</b>	<b>5</b>	<b>100.0</b>	<b>74</b>	<b>100.0</b>	<b>16</b>	<b>100.0</b>
<b>FEMALES</b>																
Neoplasm Malignant	1	3.0	-	-	-	-	2	6.9	1	12.5	-	-	-	-	-	-
Carcinoma NOS	-	-	-	-	-	-	1	3.4	-	-	1	50.0	-	-	-	-
Transitional Cell Carc.	-	-	-	-	-	-	1	3.4	-	-	-	-	-	-	-	-
Adeno Carcinoma	2	6.1	1	10.0	1	12.5	-	-	-	-	-	-	-	-	-	-
Clear Cell Adeno Carc.	10	30.3	4	40.0	5	62.5	16	55.2	3	37.5	1	50.0	13	38.2	6	50.0
Renal Cell Carcinoma	1	3.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Nephroblastoma	11	33.3	4	40.0	2	25.0	7	24.1	3	37.5	-	-	20	58.8	4	33.3
Others	8	24.2	1	10.0	-	-	2	6.9	1	12.5	-	-	1	2.9	2	16.7
<b>All Microscopic</b>	<b>33</b>	<b>100.0</b>	<b>10</b>	<b>100.0</b>	<b>8</b>	<b>100.0</b>	<b>29</b>	<b>100.0</b>	<b>8</b>	<b>100.0</b>	<b>2</b>	<b>100.0</b>	<b>34</b>	<b>100.0</b>	<b>12</b>	<b>100.0</b>

**Brain, NS (ICD-10: C70-C72)****Table 9.13: Number (#) and Relative Proportion (%) of Different Histologic Types**

Histologic Type	TMH		KMIO		CI (WIA)		RCC - TVM		AMC		BBCI		PGIMER		BRAIRCH	
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
<b>MALES</b>																
Neoplasm Malignant	1	1.1	-	-	-	-	1	3.4	2	18.2	-	-	-	-	-	-
Gliomas	12	13.0	3	13.0	-	-	6	20.7	-	-	2	28.6	35	7.0	12	30.0
Ependymoma	4	4.3	8	34.8	-	-	1	3.4	-	-	-	-	17	3.4	3	7.5
Astrocytoma	21	22.8	1	4.3	-	-	9	31.0	7	63.6	2	28.6	99	19.7	-	-
Glioblastoma	35	38.0	4	17.4	-	-	6	20.7	-	-	1	14.3	170	33.8	3	7.5
Oligodendroglioma	11	12.0	5	21.7	-	-	3	10.3	-	-	-	-	74	14.7	7	17.5
Medulloblastoma	3	3.3	1	4.3	-	-	-	-	-	-	-	-	49	9.7	4	10.0
Others	5	5.4	1	4.3	1	100.0	3	10.3	2	18.2	2	28.6	59	11.7	11	27.5
<b>All Microscopic</b>	<b>92</b>	<b>100.0</b>	<b>23</b>	<b>100.0</b>	<b>1</b>	<b>100.0</b>	<b>29</b>	<b>100.0</b>	<b>11</b>	<b>100.0</b>	<b>7</b>	<b>100.0</b>	<b>503</b>	<b>100.0</b>	<b>40</b>	<b>100.0</b>
<b>FEMALES</b>																
Neoplasm Malignant	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gliomas	5	10.2	5	38.5	-	-	1	5.9	-	-	-	-	23	9.1	3	27.3
Ependymoma	6	12.2	-	-	-	-	-	-	-	-	-	-	12	4.7	1	9.1
Astrocytoma	6	12.2	-	-	-	-	7	41.2	2	66.7	-	-	50	19.7	3	27.3
Glioblastoma	16	32.7	3	23.1	-	-	4	23.5	-	-	-	-	74	29.1	2	18.2
Oligodendroglioma	10	20.4	1	7.7	-	-	1	5.9	1	33.3	-	-	45	17.7	-	-
Medulloblastoma	2	4.1	-	-	-	-	1	5.9	-	-	-	-	14	5.5	1	9.1
Others	4	8.2	4	30.8	-	-	3	17.6	-	-	3	100.0	36	14.2	1	9.1
<b>All Microscopic</b>	<b>49</b>	<b>100.0</b>	<b>13</b>	<b>100.0</b>	-	-	<b>17</b>	<b>100.0</b>	<b>3</b>	<b>100.0</b>	<b>3</b>	<b>100.0</b>	<b>254</b>	<b>100.0</b>	<b>11</b>	<b>100.0</b>

**Thyroid Gland (ICD-10: C73)****Table 9.14: Number (#) and Relative Proportion (%) of Different Histologic Types**

Histologic Type	TMH		KMIO		CI (WIA)		RCC - TVM		AMC		BBCI		PGIMER		BRAIRCH	
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
<b>MALES</b>																
Neoplasm Malignant	2	2.5	-	-	1	4.8	3	3.0	1	25.0	-	-	-	-	-	-
Other Carcinomas	3	3.8	1	3.4	-	-	3	3.0	-	-	-	-	2	25.0	1	9.1
Undifferentiated Carc.	2	2.5	-	-	-	-	7	7.0	-	-	2	14.3	1	12.5	-	-
Papillary Carc. NOS	5	6.3	9	31.0	-	-	-	-	-	-	4	28.6	1	12.5	4	36.4
Papillary Adeno Carc.	48	60.0	13	44.8	17	81.0	69	69.0	-	-	-	-	-	-	-	-
Follicular Carcinoma	2	2.5	-	-	-	-	1	1.0	2	50.0	2	14.3	1	12.5	2	18.2
Mixed Papi. & Folli. Carc.	12	15.0	3	10.3	-	-	11	11.0	-	-	2	14.3	-	-	3	27.3
Medullary Carcinoma	6	7.5	3	10.3	2	9.5	6	6.0	-	-	2	14.3	3	37.5	1	9.1
Others	-	-	-	-	1	4.8	-	-	1	25.0	2	14.3	-	-	-	-
<b>All Microscopic</b>	<b>80</b>	<b>100.0</b>	<b>29</b>	<b>100.0</b>	<b>21</b>	<b>100.0</b>	<b>100</b>	<b>100.0</b>	<b>4</b>	<b>100.0</b>	<b>14</b>	<b>100.0</b>	<b>8</b>	<b>100.0</b>	<b>11</b>	<b>100.0</b>
<b>FEMALES</b>																
Neoplasm Malignant	3	2.3	2	3.0	5	15.6	13	5.5	2	16.7	-	-	2	14.3	-	-
Other Carcinomas	4	3.1	2	3.0	1	3.1	7	3.0	1	8.3	-	-	1	7.1	2	13.3
Undifferentiated Carc.	3	2.3	-	-	-	-	6	2.5	-	-	7	15.9	2	14.3	1	6.7
Papillary Carc. NOS	2	1.5	19	28.8	-	-	1	0.4	2	16.7	12	27.3	1	7.1	4	26.7
Papillary Adeno Carc.	65	49.6	31	47.0	14	43.8	160	67.5	-	-	-	-	-	-	-	-
Follicular Carcinoma	6	4.6	1	1.5	-	-	-	-	3	25.0	4	9.1	4	28.6	1	6.7
Mixed Papi. & Folli. Carc.	42	32.1	8	12.1	11	34.4	44	18.6	-	-	18	40.9	1	7.1	3	20.0
Medullary Carcinoma	6	4.6	1	1.5	1	3.1	5	2.1	1	8.3	2	4.5	2	14.3	4	26.7
Others	-	-	2	3.0	-	-	1	0.4	3	25.0	1	2.3	1	7.1	-	-
<b>All Microscopic</b>	<b>131</b>	<b>100.0</b>	<b>66</b>	<b>100.0</b>	<b>32</b>	<b>100.0</b>	<b>237</b>	<b>100.0</b>	<b>12</b>	<b>100.0</b>	<b>44</b>	<b>100.0</b>	<b>14</b>	<b>100.0</b>	<b>15</b>	<b>100.0</b>



## Tumours of Lymphoid and Haematopoietic System (ICD-10: C81-C85 and C90-C96)

**Table 9.15: Number (#) and Relative Proportion (%) of Different Histologic Types**

Histologic Type	TMH		KMIO		CI (WIA)		RCC - TVM		AMC		BBCI		PGIMER		BRAIRCH	
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
<b>MALES</b>																
NHL	347	31.8	57	23.1	61	23.1	394	26.4	26	37.1	94	64.8	270	24.6	156	33.1
HD	144	13.2	29	11.7	34	12.9	152	10.2	9	12.9	21	14.5	107	9.7	51	10.8
MM	80	7.3	14	5.7	26	9.8	187	12.6	10	14.3	20	13.8	108	9.8	75	15.9
Leukaemias	511	46.9	147	59.5	141	53.4	734	49.3	25	35.7	10	6.9	610	55.5	187	39.7
Others	8	0.7	-	-	2	0.8	23	1.5	-	-	-	-	4	0.4	2	0.4
<b>All Microscopic</b>	<b>1090</b>	<b>100.0</b>	<b>247</b>	<b>100.0</b>	<b>264</b>	<b>100.0</b>	<b>1490</b>	<b>100.0</b>	<b>70</b>	<b>100.0</b>	<b>145</b>	<b>100.0</b>	<b>1099</b>	<b>100.0</b>	<b>471</b>	<b>100.0</b>
<b>FEMALES</b>																
NHL	147	31.8	25	20.2	41	28.9	246	24.8	16	45.7	38	58.5	132	23.6	64	32.2
HD	41	8.9	15	12.1	18	12.7	80	8.1	1	2.9	6	9.2	50	8.9	11	5.5
MM	37	8.0	10	8.1	16	11.3	146	14.7	5	14.3	11	16.9	57	10.2	40	20.1
Leukaemias	229	49.6	73	58.9	67	47.2	503	50.8	13	37.1	10	15.4	318	56.8	82	41.2
Others	8	1.7	1	0.8	-	-	15	1.5	-	-	-	-	3	0.5	2	1.0
<b>All Microscopic</b>	<b>462</b>	<b>100.0</b>	<b>124</b>	<b>100.0</b>	<b>142</b>	<b>100.0</b>	<b>990</b>	<b>100.0</b>	<b>35</b>	<b>100.0</b>	<b>65</b>	<b>100.0</b>	<b>560</b>	<b>100.0</b>	<b>199</b>	<b>100.0</b>

NHL = Non-Hodgkin's Lymphoma; HD = Hodgkin's Disease; MM = Multiple Myeloma

## Hodgkin's Disease (ICD-10: C81)

**Table 9.16: Number (#) and Relative Proportion (%) of Different Histologic Types**

Histologic Type	TMH		KMIO		CI (WIA)		RCC - TVM		AMC		BBCI		PGIMER		BRAIRCH	
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
<b>MALES</b>																
Hodgkin's Disease NOS	41	28.5	14	48.3	9	26.5	12	7.9	5	55.6	17	81.0	79	73.8	46	90.2
HD LP	15	10.4	1	3.4	1	2.9	20	13.2	3	33.3	2	9.5	-	-	-	-
HD MC	49	34.0	7	24.1	15	44.1	47	30.9	-	-	-	-	8	7.5	2	3.9
HD LD	-	-	1	3.4	1	2.9	2	1.3	1	11.1	-	-	-	-	-	-
HD Nodular Sclerosis	33	22.9	6	20.7	7	20.6	71	46.7	-	-	2	9.5	19	17.8	2	3.9
Others	6	4.2	-	-	1	2.9	-	-	-	-	-	-	1	0.9	1	2.0
<b>All Microscopic</b>	<b>144</b>	<b>100.0</b>	<b>29</b>	<b>100.0</b>	<b>34</b>	<b>100.0</b>	<b>152</b>	<b>100.0</b>	<b>9</b>	<b>100.0</b>	<b>21</b>	<b>100.0</b>	<b>107</b>	<b>100.0</b>	<b>51</b>	<b>100.0</b>
<b>FEMALES</b>																
Hodgkin's Disease NOS	11	26.8	9	60.0	3	16.7	6	7.5	1	100.0	4	66.7	37	74.0	11	100.0
HD LP	2	4.9	-	-	-	-	3	3.8	-	-	-	-	-	-	-	-
HD MC	17	41.5	4	26.7	8	44.4	17	21.3	-	-	-	-	4	8.0	-	-
HD LD	-	-	-	-	-	-	3	3.8	-	-	-	-	-	-	-	-
HD Nodular Sclerosis	9	22.0	2	13.3	7	38.9	51	63.8	-	-	2	33.3	9	18.0	-	-
Others	2	4.9	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>All Microscopic</b>	<b>41</b>	<b>100.0</b>	<b>15</b>	<b>100.0</b>	<b>18</b>	<b>100.0</b>	<b>80</b>	<b>100.0</b>	<b>1</b>	<b>100.0</b>	<b>6</b>	<b>100.0</b>	<b>50</b>	<b>100.0</b>	<b>11</b>	<b>100.0</b>

LP = Lymphocyte Predominant; MC = Mixed Cellularity; LD = Lymphocyte Depletion

## Leukaemias (ICD-10: C91-C95)

**Table 9.17: Number (#) and Relative Proportion (%) of Different Histologic Types**

Histologic Type	TMH		KMIO		CI (WIA)		RCC - TVM		AMC		BBCI		PGIMER		BRAIRCH	
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
<b>MALES</b>																
Acute Lymph. Leuk.	221	43.2	58	39.5	60	42.6	315	42.9	12	48.0	4	40.0	370	60.7	71	38.0
Chronic Lymph. Leuk.	21	4.1	7	4.8	9	6.4	23	3.1	-	-	-	-	36	5.9	10	5.3
Other Lymph. Leuk.	-	-	13	8.8	-	-	11	1.5	-	-	-	-	-	-	1	0.5
Acute Myeloid Leuk.	89	17.4	16	10.9	13	9.2	108	14.7	3	12.0	1	10.0	35	5.7	40	21.4
Chronic Myeloid Leuk.	135	26.4	39	26.5	50	35.5	126	17.2	10	40.0	5	50.0	150	24.6	33	17.6
Other Myeloid Leuk.	4	0.8	-	-	1	0.7	-	-	-	-	-	-	4	0.7	-	-
Others	41	8.0	14	9.5	8	5.7	151	20.6	-	-	-	-	15	2.5	32	17.1
<b>All Microscopic</b>	<b>511</b>	<b>100.0</b>	<b>147</b>	<b>100.0</b>	<b>141</b>	<b>100.0</b>	<b>734</b>	<b>100.0</b>	<b>25</b>	<b>100.0</b>	<b>10</b>	<b>100.0</b>	<b>610</b>	<b>100.0</b>	<b>187</b>	<b>100.0</b>
<b>FEMALES</b>																
Acute Lymph. Leuk.	79	34.5	29	39.7	32	47.8	189	37.6	4	30.8	5	50.0	142	44.7	22	26.8
Chronic Lymph. Leuk.	4	1.7	2	2.7	3	4.5	11	2.2	2	15.4	-	-	20	6.3	3	3.7
Other Lymph. Leuk.	-	-	5	6.8	-	-	3	0.6	-	-	-	-	-	-	1	1.2
Acute Myeloid Leuk.	64	27.9	8	11.0	8	11.9	96	19.1	5	38.5	2	20.0	21	6.6	34	41.5
Chronic Myeloid Leuk.	52	22.7	24	32.9	19	28.4	54	10.7	1	7.7	2	20.0	129	40.6	14	17.1
Other Myeloid Leuk.	3	1.3	-	-	1	1.5	-	-	-	-	-	-	1	0.3	-	-
Others	27	11.8	5	6.8	4	6.0	150	29.8	1	7.7	1	10.0	5	1.6	8	9.8
<b>All Microscopic</b>	<b>229</b>	<b>100.0</b>	<b>73</b>	<b>100.0</b>	<b>67</b>	<b>100.0</b>	<b>503</b>	<b>100.0</b>	<b>13</b>	<b>100.0</b>	<b>10</b>	<b>100.0</b>	<b>318</b>	<b>100.0</b>	<b>82</b>	<b>100.0</b>

*Lymph. Leuk.* = *Lymphoid Leukaemia*

**“If you put me in charge of the medical research budget, I would cancel all primary research, I would cancel all new trials, for just one year, and I would spend the money exclusively on making sure that we make the best possible use of the clinical evidence that we already have”**

*- Ben Goldacre*